Our top pick for
ProPhase Labs, Inc is a drug manufacturers-specialty & generic business based in the US. ProPhase Labs shares (PRPH) are listed on the NASDAQ and all prices are listed in US Dollars. ProPhase Labs employs 48 staff and has a trailing 12-month revenue of around USD$12.5 million.
|Latest market close||USD$9.18|
|52-week range||USD$1.37 - USD$11.82|
|50-day moving average||USD$9.3509|
|200-day moving average||USD$4.8642|
|Wall St. target price||USD$15.55|
|Dividend yield||N/A (13.16%)|
|Earnings per share (TTM)||USD$-0.327|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-33.48%|
|1 month (2020-12-16)||-14.60%|
|3 months (2020-10-15)||67.21%|
|6 months (2020-07-15)||477.36%|
|1 year (2020-01-15)||401.64%|
|2 years (2019-01-15)||204.98%|
|3 years (2018-01-12)||285.71%|
|5 years (2016-01-15)||555.71%|
|Revenue TTM||USD$12.5 million|
|Gross profit TTM||USD$2.6 million|
|Return on assets TTM||-5.78%|
|Return on equity TTM||-13.79%|
|Market capitalisation||USD$125.6 million|
TTM: trailing 12 months
There are currently 123,015 ProPhase Labs shares held short by investors – that's known as ProPhase Labs's "short interest". This figure is 9.7% down from 136,285 last month.
There are a few different ways that this level of interest in shorting ProPhase Labs shares can be evaluated.
ProPhase Labs's "short interest ratio" (SIR) is the quantity of ProPhase Labs shares currently shorted divided by the average quantity of ProPhase Labs shares traded daily (recently around 61816.582914573). ProPhase Labs's SIR currently stands at 1.99. In other words for every 100,000 ProPhase Labs shares traded daily on the market, roughly 1990 shares are currently held short.
However ProPhase Labs's short interest can also be evaluated against the total number of ProPhase Labs shares, or, against the total number of tradable ProPhase Labs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ProPhase Labs's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ProPhase Labs shares in existence, roughly 10 shares are currently held short) or 0.0144% of the tradable shares (for every 100,000 tradable ProPhase Labs shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ProPhase Labs.
Find out more about how you can short ProPhase Labs stock.
We're not expecting ProPhase Labs to pay a dividend over the next 12 months.
ProPhase Labs's shares were split on a 2:1 basis on 23 January 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ProPhase Labs shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ProPhase Labs shares which in turn could have impacted ProPhase Labs's share price.
Over the last 12 months, ProPhase Labs's shares have ranged in value from as little as $1.37 up to $11.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProPhase Labs's is 0.2394. This would suggest that ProPhase Labs's shares are less volatile than average (for this exchange).
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers COVID-19 and other respiratory pathogen panel testing services. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.